Systematic
reviews and meta-analyses in this domain only -> health sciences; field
-> clinical medicine (and 32 subfields as classified by Ioannidis et al. 2023); and focussing on therapies,
medicines (including adverse effects of those), drugs, devices, interventions
will all be eligible. Studies published in any language will be included. Only ‘new
systematic reviews’, published in 2022 and 2023 and those that had searched in databases, registers and
other sources (for the available primary studies) will be eligible.
We
will exclude SRs of diagnostic tests/tools, predictive, prognostic or
prognostic modelling studies, qualitative studies; narrative, umbrella,
scoping, aetiological, prevalence/incidence, realists, mixed-methods, rapid, scoping
reviews, and any reviews not structured as SRs or meta-analyses. Will also
exclude updated (or update) systematic reviews; and those published outside of
the above-mentioned timeframe as well as SRs published as abstracts only. SRs
of allied health professions e.g., physiotherapy, nursing will be excluded as
well as those in social sciences, e.g., psychology (as per the above criteria).